Potassium
Metal that 5 drugs act on.
- Drugs that act on it: 5
- Approved: 4
- In phases 1 to 3: 1
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
Approved4
Phase 31
Phase 20
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
| Sodium zirconium cyclosilicate | Approved | AstraZeneca Pharmaceuticals | Small molecule | Chelating agent | 8 |
| Patiromer calcium | Approved | CSL | Small molecule | Chelating agent | 5 |
| Sodium polystyrene sulfonate | Approved | Concordia Pharmaceuticals | Small molecule | Sequestering agentPotassium sequestering agent | 2 |
| Patiromer sorbitex calcium | Approved | CSL | Small molecule | Chelating agent | 0 |
| Patiromer | Phase 3 | CSL | Small molecule | Chelating agent | 5 |
| A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia | Sodium zirconium cyclosilicate | Phase 4 | Recruiting | AstraZeneca | Nov 18, 2026 |
| OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension) | Sodium zirconium cyclosilicate | Phase 2 | Not yet recruiting | Sahlgrenska University Hospital | May 8, 2026 |
| Swedish Cardiac And Renal Failure Study-1 | Sodium zirconium cyclosilicate | Phase 2 | Recruiting | Karolinska Institutet | Jun 19, 2025 |
| Patiromer and Diet/hrQoL in Chronic Dialysis | Patiromer, Patiromer calcium | Phase 3 | Recruiting | Mario Negri Institute for Pharmacological Research | Mar 5, 2025 |
| the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients | Sodium zirconium cyclosilicate | Phase 4 | Not yet recruiting | Qianfoshan Hospital | Dec 16, 2024 |
| Keeping RAASi Treatment With Optimal Potassium Control | Sodium zirconium cyclosilicate | Phase 3 | Recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | Aug 29, 2024 |
| A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients | Sodium zirconium cyclosilicate | Phase 3 | Recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | Aug 29, 2024 |
| Potassium Correction for RAAS Optimization in Chronic Kidney Disease | Patiromer, Patiromer calcium | Phase 4 | Recruiting | University Medical Center Groningen | Feb 13, 2024 |
| Incremental Hemodialysis: The TwoPlus Trial | Patiromer, Patiromer calcium | Not applicable | Recruiting | Wake Forest University Health Sciences | Apr 25, 2023 |
| Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels | Patiromer, Patiromer calcium | Phase 2 | Recruiting | Vifor Pharma, Inc. | Mar 13, 2023 |
| Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease | Patiromer, Patiromer calcium | Not applicable | Active, not recruiting | Nand Wadhwa | Sep 20, 2021 |
| OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure | Sodium polystyrene sulfonate, Sodium zirconium cyclosilicate | Phase 2 | Active, not recruiting | Michael Fu | Mar 9, 2021 |
| An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia | Sodium zirconium cyclosilicate | Phase 3 | Recruiting | AstraZeneca | Jan 23, 2019 |
| Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®) | Sodium polystyrene sulfonate | Not applicable | Active, not recruiting | Societe ACTIVBIOMAT | Apr 14, 2017 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3545434, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets